Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth

Seminars in Reproductive Medicine

Volumn 28, Issue 3, 2010, Pages 260-273

  Yoshida, Shigeki ^a   Ohara, Noriyuki ^a   Xu, Qin ^a   Chen, Wei ^a   Wang, Jiayin ^a   Nakabayashi, Koji ^a   Sasaki, Hiroko ^a   Morikawa, Akira ^a   Maruo, Takeshi ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE CHILDREN S HOSPITAL   (Japan)

Author keywords

Angiogenic factor; Apoptosis; Collagen; Endoplasmic reticulum stress; Extracellular matrix; Growth factor; Leiomyoma; Myometrium; Progesterone receptor modulator; Proliferation

Indexed keywords

ANGIOGENIC FACTOR; ASOPRISNIL; MIFEPRISTONE; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT SOMATOMEDIN C; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ULIPRISNIL ACETATE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL TYPE; CELL VIABILITY; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX; HUMAN; HYPOTHESIS; IN VITRO STUDY; MITOCHONDRION; MYOMETRIUM; NONHUMAN; REVIEW; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR VOLUME; UTERUS MYOMA;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL PROLIFERATION; ENDOPLASMIC RETICULUM; ESTRENES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; LEIOMYOMA; MYOMETRIUM; NORPREGNADIENES; OXIMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PROGESTERONE; STRESS, PHYSIOLOGICAL; UTERINE NEOPLASMS;

EID: 77951593752     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1251483     Document Type: Review

References (131)

1. Rein M S., Barbieri R L., Friedman A J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995 172 (1 Pt 1) 14-18
2. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997 82 (1) 293-299 (Pubitemid 27021314)
3. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998 83 (6) 2192-2198 (Pubitemid 28496358)
4. Kurachi O, Matsuo H, Samoto T, Maruo T. Tumor necrosis factor-βalpha expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 2001 86 (5) 2275-2280 (Pubitemid 32472952)
5. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004 10 (3) 207-220 (Pubitemid 38750141)
6. Harrison-Woolrych M L., Charnock-Jones D S., Smith S K. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994 78 (5) 1179-1184
7. Maruo T, Samoto T, Matsuo H, Shimomura Y, Mochizuki M. Regulation of proliferative potential and Bcl-2 oncoprotein expression in human uterine leiomyoma by sex steroid hormones In: Kuramoto H, Gurpide E In Vitro Biology of Sex Steroid Hormone Action. Tokyo, Japan Churchill Livingstone 1996 251-263
8. Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2001 86 (11) 5593-5599 (Pubitemid 33070293)
9. Yamada T, Nakago S, Kurachi O et al. Progesterone down-regulates insulin-like growth factor-βI expression in cultured human uterine leiomyoma cells. Hum Reprod 2004 19 815-821 (Pubitemid 38456044)
10. Leonhardt S A., Edwards D P. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood) 2002 227 969-980
11. Kastner P, Krust A, Turcotte B et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990 9 (5) 1603-1614 (Pubitemid 20137018)
12. Vegeto E, Shahbaz M M., Wen D X., Goldman M E., O'Malley B W., McDonnell D P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993 7 (10) 1244-1255 (Pubitemid 23319107)
13. Wen D X., Xu Y-F, Mais D E., Goldman M E., McDonnell D P. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 1994 14 (12) 8356-8364
14. Brandon D D., Bethea C L., Strawn E Y. et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993 169 (1) 78-85 (Pubitemid 23223932)
15. Viville B, Charnock-Jones D S., Sharkey A M., Wetzka B, Smith S K. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997 12 (4) 815-822 (Pubitemid 27223053)
16. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999 14 (11) 2844-2850 (Pubitemid 29520705)
17. Tiltman A J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 1985 4 (2) 89-96 (Pubitemid 15070504)
18. Carr B R., Marshburn P B., Weatherall P T. et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993 76 (5) 1217-1223
19. Friedman A J., Daly M, Juneau-Norcross M et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin add-back regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993 76 (6) 1439-1445 (Pubitemid 23164358)
20. Kettel L M., Murphy A A., Morales A J., Yen S SC. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994 9 (suppl 1) 116-120
21. Murphy A A., Morales A J., Kettel L M., Yen S SC. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995 64 (1) 187-190
22. Eisinger S H., Meldrum S, Fiscella K, le Roux H D., Guzick D S. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003 101 (2) 243-250 (Pubitemid 36170124)
23. Chwalisz K, Perez M C., Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005 26 (3) 423-438 (Pubitemid 40686652)
24. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel C A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007 87 (6) 1399-1412 (Pubitemid 46829155)
25. Levens E D., Potlog-Nahari C, Armstrong A Y. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008 111 (5) 1129-1136 (Pubitemid 351620347)
26. Wilkens J, Chwalisz K, Han C et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008 93 (12) 4664-4671
27. Attardi B J., Burgenson J, Hild S A., Reel J R., Blye R P. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002 188 (1-2) 111-123 (Pubitemid 34242671)
28. Blithe D L., Nieman L K., Blye R P., Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003 68 (1013) 1013-1017 (Pubitemid 37532426)
29. Gainer E E., Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003 68 (1013) 1005-1011 (Pubitemid 37532425)
30. Hild S A., Reel J R., Hoffman L H., Blye R P. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 2000 15 (4) 822-829
31. Horne F M., Blithe D L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007 13 (6) 567-580
32. Ravet S, Munaut C, Blacher S et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab 2008 93 (11) 4525-4531 (Pubitemid 352789556)
33. Wilkens J, Williams A RW, Chwalisz K, Han C, Cameron I T., Critchley H O. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Hum Reprod 2009 24 1036-1044
34. Xu Q, Takekida S, Ohara N et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005 90 (2) 953-961 (Pubitemid 40279221)
35. Chen W, Ohara N, Wang J et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006 91 (4) 1296-1304
36. Robbins B A., de la Vega D, Ogata K, Tan E M., Nakamura R M. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987 111 841-845 (Pubitemid 17121990)
37. Wang J, Ohara N, Wang Z et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006 21 (7) 1869-1877 (Pubitemid 44028263)
38. Singh A B., Harris R C. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005 17 (10) 1183-1193
39. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 2005 16 (4-5) 407-420 (Pubitemid 41022011)
40. de Caestecker M. The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev 2004 15 (1) 1-11 (Pubitemid 38121286)
41. Lutz M, Knaus P. Integration of the TGF-β pathway into the cellular signalling network. Cell Signal 2002 14 (12) 977-988 (Pubitemid 35279422)
42. Wrana J L., Attisano L, Wieser R, Ventura F, Massagu J. Mechanism of activation of the TGF-β receptor. Nature 1994 370 (6488) 341-347
43. Lawler S, Feng X-H, Chen R-H et al. The type II transforming growth factor-β receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 1997 272 (23) 14850-14859 (Pubitemid 27251755)
44. Lee B S., Nowak R A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-β 3 (TGF 3) and altered responses to the antiproliferative effects of TGF J Clin Endocrinol Metab 2001 86 (2) 913-920
45. Lange C A. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 2004 18 (2) 269-278
46. Faivre E, Skildum A, Pierson-Mullany L, Lange C A. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 2005 70 (57) 418-426 (Pubitemid 40616040)
47. Lange C A., Richer J K., Shen T, Horwitz K B. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998 273 (47) 31308-31316 (Pubitemid 28533147)
48. ras /Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998 17 2008-2018 (Pubitemid 28154530)
49. Wang S, El-Deiry W S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003 22 (53) 8628-8633 (Pubitemid 38019198)
50. Riedl S J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004 5 (11) 897-907 (Pubitemid 39486541)
51. Shiozaki E N., Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004 29 486-494 (Pubitemid 39158872)
52. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004 13 (8) 1979-1987 (Pubitemid 38989605)
53. Cohen G M. Caspases: the executioners of apoptosis. Biochem J 1997 326 (Pt 1) 1-16
54. Bouchard V J., Rouleau M, Poirier G G. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003 31 (6) 446-454 (Pubitemid 36793950)
55. Pieper A A., Verma A, Zhang J, Snyder S H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999 20 (4) 171-181 (Pubitemid 29222762)
56. Reed J C., Jurgensmeier J M., Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1998 1366 (12) 127-137 (Pubitemid 28467027)
57. Yin P, Lin Z, Cheng Y-H et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 2007 92 (11) 4459-4466 (Pubitemid 350074770)
58. Sheikh M S., Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004 4 (1) 97-104 (Pubitemid 38332568)
59. Yagita H, Takeda K, Hayakawa Y, Smyth M J., Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004 95 (10) 777-783 (Pubitemid 39545582)
60. Hoffman P J., Milliken D B., Gregg L C., Davis R R., Gregg J P. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004 82 639-649
61. Sasaki H, Ohara N, Xu Q et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007 92 (2) 616-623 (Pubitemid 46255305)
62. Schimmer A D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004 64 (20) 7183-7190
63. Deveraux Q L., Reed J C. IAP family proteinssuppressors of apoptosis. Genes Dev 1999 13 (3) 239-252
64. Zhang X D., Zhang X Y., Gray C P., Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001 61 (19) 7339-7348 (Pubitemid 32946534)
65. Shi R-X, Ong C-N, Shen H-M. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 2005 65 (17) 7815-7823 (Pubitemid 41297257)
66. Walocha J A., Litwin J A., Miodoski A J. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003 18 (5) 1088-1093
67. Hague S, Zhang L, Oehler M K. et al. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000 6 (7) 2808-2814 (Pubitemid 30482121)
68. Gentry C C., Okolo S O., Fong L F., Crow J C., Maclean A B., Perrett C W. Quantification of vascular endothelial growth factor-β A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001 101 (6) 691-695 (Pubitemid 33135352)
69. Cross M J., Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003 28 (9) 488-494 (Pubitemid 38340413)
70. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 9 (6) 669-676 (Pubitemid 36749215)
71. Brown L F., Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe M L. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997 76 (2) 245-255 (Pubitemid 27082068)
72. Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees M C. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998 16 (3) 409-415 (Pubitemid 28052295)
73. Ribatti D, Guidolin D, Conconi M T. et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 2003 22 (41) 6458-6461 (Pubitemid 37281693)
74. Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology 1997 138 (6) 2615-2620 (Pubitemid 27215270)
75. Greb R R., Heikinheimo O, Williams R F., Hodgen G D., Goodman A L. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod 1997 12 (6) 1280-1292 (Pubitemid 27273561)
76. Ancelin M, Buteau-Lozano H, Meduri G et al. A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci U S A 2002 99 (9) 6023-6028 (Pubitemid 34493258)
77. Thota C, Gangula P RR, Dong Y L., Yallampalli C. Changes in the expression of calcitonin receptor-like receptor, receptor activity-modifying protein (RAMP) 1, RAMP2, and RAMP3 in rat uterus during pregnancy, labor, and by steroid hormone treatments. Biol Reprod 2003 69 (4) 1432-1437 (Pubitemid 37173882)
78. Thota C, Yallampalli C. Progesterone upregulates calcitonin gene-related peptide and adrenomedullin receptor components and cyclic adenosine 3'5-monophosphate generation in Eker rat uterine smooth muscle cell line. Biol Reprod 2005 72 (2) 416-422 (Pubitemid 40129718)
79. Xu Q, Ohara N, Chen W et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006 21 (9) 2408-2416 (Pubitemid 44530620)
80. Shiraishi T, Yoshida T, Nakata S et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005 65 (14) 6364-6370 (Pubitemid 40994423)
81. Zhang K, Kaufman R J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2006 66 (2, suppl 1) S102-S109 (Pubitemid 43739994)
82. Szegezdi E, Logue S E., Gorman A M., Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006 7 (9) 880-885 (Pubitemid 44523966)
83. Xu C, Bailly-Maitre B, Reed J C. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005 115 (10) 2656-2664 (Pubitemid 41434389)
84. Kadowaki H, Nishitoh H, Ichijo H. Survival and apoptosis signals in ER stress: the role of protein kinases. J Chem Neuroanat 2004 28 (12) 93-100 (Pubitemid 39195254)
85. Harding H P., Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999 397 (6716) 271-274 (Pubitemid 29051178)
86. Marciniak S J., Yun C Y., Oyadomari S et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004 18 (24) 3066-3077 (Pubitemid 39658175)
87. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J 2005 24 (6) 1243-1255 (Pubitemid 40516607)
88. Annis M G., Zamzami N, Zhu W et al. Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene 2001 20 (16) 1939-1952 (Pubitemid 32458026)
89. Zong W-X, Li C, Hatzivassiliou G et al. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 2003 162 (1) 59-69 (Pubitemid 36859535)
90. Xu Q, Ohara N, Liu J et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Endocrinol Metab 2007 293 E1002-E1011 (Pubitemid 47535831)
91. Oyadomari S, Koizumi A, Takeda K et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002 109 (4) 525-532 (Pubitemid 34171784)
92. Zinszner H, Kuroda M, Wang X Z. et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998 12 (7) 982-995 (Pubitemid 28204605)
93. McCullough K D., Martindale J L., Klotz L-O, Aw T-Y, Holbrook N J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001 21 (4) 1249-1259
94. Adler H T., Chinery R, Wu D Y. et al. Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol 1999 19 (10) 7050-7060 (Pubitemid 29441887)
95. Ma Y, Hendershot L M. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem 2003 278 (37) 34864-34873 (Pubitemid 37102245)
96. Novoa I, Zeng H, Harding H P., Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2 J Cell Biol 2001 153 (5) 1011-1022 (Pubitemid 34289240)
97. Boyce M, Bryant K F., Jousse C et al. A selective inhibitor of eIF2 dephosphorylation protects cells from ER stress. Science 2005 307 (5711) 935-939 (Pubitemid 40229232)
98. Örd D, Örd T. Mouse NIPK interacts with ATF4 and affects its transcriptional activity. Exp Cell Res 2003 286 (2) 308-320 (Pubitemid 36566443)
99. Örd D, Örd T. Characterization of human NIPK (TRB3, SKIP3) gene activation in stressful conditions. Biochem Biophys Res Commun 2005 330 (1) 210-218 (Pubitemid 40394954)
100. Häcki J, Egger L, Monney L et al. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 2000 19 (19) 2286-2295 (Pubitemid 30307204)
101. Wang N S., Unkila M T., Reineks E Z., Distelhorst C W. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J Biol Chem 2001 276 (47) 44117-44128 (Pubitemid 37383984)
102. Wei M C., Zong W-X, Cheng E HY et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001 292 (5517) 727-730
103. Bassik M C., Scorrano L, Oakes S A., Pozzan T, Korsmeyer S J. Phosphorylation of BCL-2 regulates ER Ca2+homeostasis and apoptosis. EMBO J 2004 23 (5) 1207-1216 (Pubitemid 38436884)
104. Oakes S A., Scorrano L, Opferman J T. et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A 2005 102 (1) 105-110 (Pubitemid 40094436)
105. Scorrano L, Oakes S A., Opferman J T. et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003 300 (5616) 135-139 (Pubitemid 36423046)
106. Nutt L K., Pataer A, Pahler J et al. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+stores. J Biol Chem 2002 277 (11) 9219-9225 (Pubitemid 34953002)
107. Yamaguchi H, Wang H-G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 2004 279 (44) 45495-45502 (Pubitemid 39491535)
108. Chirco R, Liu X W., Jung K K., Kim H R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006 25 (1) 99-113 (Pubitemid 43723986)
109. Gelse K, PÖschl E, Aigner T. Collagensstructure, function, and biosynthesis. Adv Drug Deliv Rev 2003 55 (12) 1531-1546
110. Canty E G., Kadler K E. Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 2005 118 (Pt 7) 1341-1353
111. Stewart E A., Friedman A J., Peck K, Nowak R A. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 1994 79 (3) 900-906 (Pubitemid 24286424)
112. Wolaska M, Sobolewski K, Drodewicz M, Bakowski E. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol Cell Biochem 1998 189 (12) 145-152 (Pubitemid 28556559)
113. Berto A GA, Sampaio L O., Franco C RC, Cesar R M. Jr, Michelacci Y M. A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium. Biochim Biophys Acta 2003 1619 (1) 98-112
114. Wang H, Mahadevappa M, Yamamoto K et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003 80 (2) 266-276 (Pubitemid 36959779)
115. Leppert P C., Baginski T, Prupas C, Catherino W H., Pletcher S, Segars J H. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril 2004 82 (suppl 3) 1182-1187 (Pubitemid 39335936)
116. Curry T E. Jr, Osteen K G. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003 24 (4) 428-465
117. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003 92 (8) 827-839 (Pubitemid 36542523)
118. Guo H, Zucker S, Gordon M K., Toole B P., Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997 272 (1) 24-27 (Pubitemid 27021117)
119. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002 99 (4) 520-528 (Pubitemid 34461604)
120. Schmidt R, Bltmann A, Ungerer M et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006 113 (6) 834-841 (Pubitemid 43754304)
121. Chung L, Dinakarpandian D, Yoshida N et al. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 2004 23 (15) 3020-3030 (Pubitemid 39093596)
122. Inada M, Wang Y, Byrne M H. et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A 2004 101 (49) 17192-17197 (Pubitemid 39627796)
123. Aimes R T., Quigley J P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995 270 (11) 5872-5876
124. Allan J A., Docherty A J., Barker P J., Huskisson N S., Reynolds J J., Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995 309 (Pt 1) 299-306
125. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997 272 (4) 2446-2451 (Pubitemid 27058534)
126. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006 69 (3) 562-573 (Pubitemid 43139720)
127. Morikawa A, Ohara N, Xu Q et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008 23 (4) 944-951
128. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008 14 (3) 181-191 (Pubitemid 351404891)
129. Somasundaram R, Schuppan D, Type I. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J Biol Chem 1996 271 (43) 26884-26891 (Pubitemid 26359101)
130. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 2006 5 (1) 28-33 (Pubitemid 43234974)
131. Madauss K P., Grygielko E T., Deng S-J et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007 21 (5) 1066-1081 (Pubitemid 46984759)